A Canadian speciality pharmaceutical company has appointed Dublin man Conor Walshe as general manager of its European subsidiary.
Theratechnologies, which aims to improve the quality of life for HIV patients, is establishing its European head office in Dublin where Mr Walshe will be based.
Mr Walshe will oversee the building of the Dublin office and the potential launch of Trogarzo, a drug used to treat patients with multidrug resistant HIV.
Prior to joining the company's European subsidiary, Mr Walshe was a general manager and vice president at Aralez, another Canadian speciality pharmaceutical company with a presence in Dublin. He also previously worked at Perrigo, Elan and Venn Life Sciences.
Listed on the Toronto Stock Exchange and headquartered in Montréal, Theratechnologies has a market value of almost 590 million Canadian dollars (€394 million).